Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.